Publications by authors named "Leda Mannent"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

269

Total Likes

375

Extended Reach

2,161,420

Social Features

166
E
Efficacy and safety of rilzabrutinib in patients with moderate-to-severe atopic dermatitis: 16-week results from a proof-of-concept phase II clinical trial.
Leon Kircik, Athanasios Tsianakas, Fernando Valenzuela, Vincent Mikol, Gaowei Nian, Leda Mannent

Br J Dermatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial.
Ana Giménez-Arnau, Silvia Ferrucci, Moshe Ben-Shoshan, Vincent Mikol, Laurence Lucats, Leda Mannent

JAMA Dermatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy.
R Sharon Chinthrajah, Sayantani B Sindher, Kari C Nadeau, Jeffrey G Leflein, Jonathan M Spergel, Leda P Mannent

Allergy· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mild and symptom-free months in patients with chronic rhinosinusitis with nasal polyps treated with dupilumab.
Claus Bachert, Asif H Khan, Claire Hopkins, Joseph K Han, Wytske J Fokkens, Leda P Mannent

Ann Allergy Asthma Immunol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study.
Sayantani B Sindher, Kari C Nadeau, R Sharon Chinthrajah, Jeffrey G Leflein, Philippe Bégin, Leda P Mannent

Allergy· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis.
Claus Bachert, Philippe Gevaert, Brian Lipworth, Syed Shahzad Mustafa, Andrew P Lane, Leda Mannent

Allergy· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nasal brushing molecular endotyping distinguishes patients with chronic rhinosinusitis with nasal polyps with better response to dupilumab.
Kaitlyn Gayvert, Martin Desrosiers, Tanya M Laidlaw, Leda P Mannent, Kiran Patel

J Allergy Clin Immunol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.
Leonard B Bacharier, Ian D Pavord, Jorge F Maspero, Daniel J Jackson, Alessandro G Fiocchi, Leda P Mannent

J Allergy Clin Immunol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
Marcus Maurer, Thomas B Casale, Sarbjit S Saini, Moshe Ben-Shoshan, Ana M Giménez-Arnau, Leda P Mannent

J Allergy Clin Immunol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study.
Leonard B Bacharier, Theresa W Guilbert, Constance H Katelaris, Antoine Deschildre, Wanda Phipatanakul, Leda P Mannent

J Allergy Clin Immunol Pract· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
Alberto Papi, Mario Castro, Jonathan Corren, Ian D Pavord, Yuji Tohda, Leda P Mannent

Respir Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study.
Albert J Bredenoord, Evan S Dellon, Ikuo Hirano, Alfredo J Lucendo, Christoph Schlag, Leda Mannent

Gut· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study.
Leonard B Bacharier, Jorge F Maspero, Constance H Katelaris, Alessandro G Fiocchi, Remi Gagnon, Leda P Mannent

Lancet Respir Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results.
Claus Bachert, Tanya M Laidlaw, Seong H Cho, Joaquim Mullol, Brian N Swanson, Leda P Mannent

Ann Otol Rhinol Laryngol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Marc E Rothenberg, Evan S Dellon, Margaret H Collins, Ikuo Hirano, Mirna Chehade, Leda P Mannent

Lancet Gastroenterol Hepatol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization.
Jonathan Corren, Nicola A Hanania, William W Busse, Lawrence D Sher, Arman Altincatal, Leda P Mannent

Clin Exp Allergy· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma.
Daniel J Jackson, Leonard B Bacharier, Wanda Phipatanakul, Lawrence Sher, Christian Domingo, Leda P Mannent

Ann Allergy Asthma Immunol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
Gil Yosipovitch, Nicholas Mollanazar, Sonja Ständer, Shawn G Kwatra, Brian S Kim, Leda P Mannent

Nat Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies.
Jorge F Maspero, Claus Bachert, Fernando J Martinez, Nicola A Hanania, Benjamin Ortiz, Leda P Mannent

J Asthma Allergy· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.
Evan S Dellon, Marc E Rothenberg, Margaret H Collins, Ikuo Hirano, Mirna Chehade, Leda P Mannent

N Engl J Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
Michael E Wechsler, Amy D Klion, Pierluigi Paggiaro, Parameswaran Nair, Delphine Staumont-Salle, Leda P Mannent

J Allergy Clin Immunol Pract· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Amy S Paller, Eric L Simpson, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Leda P Mannent

Lancet· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial.
Lawrence D Sher, Michael E Wechsler, Klaus F Rabe, Jorge F Maspero, Nadia Daizadeh, Leda P Mannent

Chest· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases.
G Walter Canonica, Arnaud Bourdin, Anju T Peters, Martin Desrosiers, Claus Bachert, Leda P Mannent

J Allergy Clin Immunol Pract· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis